Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHUFFLE study of switching from intravenous to subcutaneous infliximab in adults with inflammatory bowel disease
NL-OMON56467Completed
- Sponsor
- Zuyderland
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 cohorts), sponsored by Zuyderland. Primary endpoints: AUC at steady state normalized to 8 weeks and AUC of one dosing interval at steady state for subcutaneous CT-P13. Started Mar 2024; status: completed.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON56467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56467.